Working in healthcare isn’t just a job. It’s a calling—to develop solutions that transform patients’ lives and help healthcare professionals provide the best care. Meet the team that inspires our employees to fulfill that purpose and ensures high performance for our shareholders.
MICHAEL F. MAHONEY
Chairman and Chief Executive Officer
Senior Vice President and President, Interventional Cardiology
DANIEL J. BRENNAN
Executive Vice President and Chief Financial Officer
Senior Vice President, General Counsel and Corporate Secretary
Senior Vice President and President, Endoscopy
Senior Vice President, Human Resources
JOSEPH M. FITZGERALD
Executive Vice President and President, Rhythm Management
Executive Vice President, Global Operations
Executive Vice President and Global Chief Medical Officer
Senior Vice President and President, Peripheral Interventions
Senior Vice President and President, Neuromodulation
DAVID A. PIERCE
Executive Vice President and President, MedSurg
Senior Vice President, Manufacturing and Supply Chain
Senior Vice President and President, Europe
Senior Vice President and President, Asia Pacific
Michael F. Mahoney became our Chairman of the Board, President, Chief Executive Officer and director in May 2016. He served as President, Chief Executive Officer and director from November 2012 to April 2016. He served as President of the Company from October 2011 to October 2012. As President of the Company, he was specifically responsible for our Cardiac Rhythm Management and Endoscopy businesses, as well as certain corporate functions.
Prior to joining the Company, he was Worldwide Chairman of the Medical Devices and Diagnostics division of Johnson & Johnson from January 2011 to September 2011 overseeing 50,000 employees and seven franchises. Prior to assuming this position, Mr. Mahoney served as Worldwide Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011.
From January 2001 through March 2007, Mr. Mahoney served as President and Chief Executive Officer of Global Healthcare Exchange (GHX), a provider of supply chain solutions and services that brings together hospitals, manufacturers, distributors and group purchasing organizations. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business.
He currently serves on the board of directors of Baxter International, Inc. Mr. Mahoney earned a B.B.A. in Finance from the University of Iowa and a M.B.A. from Wake Forest University.
Kevin Ballinger is Senior Vice President and Global President, Interventional Cardiology for Boston Scientific and a member of its Executive Committee. In this role, he is responsible for developing and bringing to market innovative solutions that diagnose and treat coronary artery disease and cardiac valve disorders.
Ballinger has more than 17 years of interventional cardiology experience. Prior to his current role, he held a variety of engineering and general management positions within Boston Scientific’s Interventional Cardiology business unit, including overseeing the development of the company’s first drug-eluting stents.
Ballinger earned a B.S. in Mechanical Engineering from Michigan Tech University and an MBA from the University of Minnesota.
Daniel J. Brennan
Executive Vice President and Chief Financial Officer
Daniel Brennan is Executive Vice President and Chief Financial Officer for Boston Scientific Corporation and a member of its Executive Committee. In this role, he is responsible for several Company functions, including Global Controllership, Corporate Finance, Treasury, Corporate Tax, Corporate Analysis and Control, and Corporate New Business Development.
Previously, he served as Senior Vice President and Corporate Controller. In this role, Brennan was responsible for the Global Controllership organization, including the Company’s accounting and financial planning processes.
Brennan joined Boston Scientific in 1996 and has served in a number of financial roles of increasing responsibility, including Assistant Corporate Controller; Vice President-Worldwide Financial & Strategic Planning; Vice President-Investor Relations, Vice President-International Finance and Vice President-Finance & Information Technology for the company’s Cardiovascular Division.
Prior to joining Boston Scientific, Brennan held several finance positions at Millipore Corporation and Standex Corporation.
Brennan is a Certified Public Accountant and earned his B.S. in Finance and Investments and his M.B.A. from Babson College.
Desiree Ralls-Morrison is our senior vice president, general counsel and corporate secretary, a position she has held since November 2017. In this role, she is responsible for providing global legal leadership across all of our businesses, regions and functions, and overseeing the company’s global compliance function. Before joining Boston Scientific she was senior vice president, general counsel and corporate secretary, and head of the global litigation, government affairs and public policy organizations, for Boehringer Ingelheim USA, Inc. since October 2013. Prior to that, she spent nine years at Johnson & Johnson, most recently as general counsel for the consumer group, and previously progressed through roles of increasing responsibility, including senior counsel, assistant general counsel, and vice president of law for the women’s health, nutritionals and over the counter businesses. Earlier in her career, Ms. Ralls-Morrison was a senior attorney and assistant counsel at Merck & Co, Inc., focusing largely on regulatory and product liability matters, and prior to that, she held litigation roles at the law firms of Kelley Drye & Warren LLP and Shipman & Goodwin LLP. She recently served on the Danbury Hospital/New Milford Hospital Board of Directors, The Inner-City Foundation for Charity and Education and the Lawyer's Collaborative for Diversity. Desiree earned her bachelor of arts in economics and political science from Wesleyan University and her juris doctor from Harvard Law School.
Senior Vice President and President, Endoscopy
Arthur Butcher is Senior Vice President and President, Endoscopy Division for Boston Scientific. In this role, he is responsible for developing and bringing to market less invasive devices for treating gastrointestinal and pulmonary conditions.
Prior to his current role, Butcher was Vice President & General Manager, Japan Endoscopy Business. Since joining the Company in 1997, he has held a variety of marketing and strategic planning management positions within the Endoscopy and Urology and Pelvic Health divisions.
Butcher holds a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from Columbia University.
Wendy Carruthers is Senior Vice President of Human Resources for Boston Scientific Corporation and a member of its Executive Committee. In this role, she provides strategic leadership to the global HR function, including HR operations, total rewards, talent management, diversity and inclusion, and community relations.
Prior to her current role, Carruthers served as Vice President of Global Talent Management for Boston Scientific, responsible for all aspects of global talent management including the design, development and implementation of global processes and systems to enable managers to identify, attract and develop people.
Carruthers has been with Boston Scientific since 2004 and was previously Vice President of Human Resources for the company’s Europe, Middle East and Africa (EMEA) region, based in Paris.
Prior to joining Boston Scientific, Carruthers was Vice President of Human Resources, Europe for global telecommunications company Cable & Wireless. She also previously worked in human resources for Diageo, a premium drinks business, and Tesco, a U.K. retailer.
A native of Great Britain, Carruthers has lived and worked in the U.K., France, Italy, Australia and the United States. She holds a B.A. First Class Honors Degree in Modern Languages and is a Fellow of the Chartered Institute of Personnel and Development. She is also on the Board of the Boston Scientific Foundation and a member of the Board of Advisors of the Greater Boston Food Bank.
Professor Ian Meredith is Executive Vice President and Global Chief Medical Officer for Boston Scientific and a member of the Executive Committee. In this role, he is responsible for leading clinical and medical affairs across Boston Scientific and providing global leadership of the company’s clinical trial strategy.
Prior to joining Boston Scientific in 2017, Professor Meredith served as Professor and Director of MonashHeart, the Cardiology service within Monash Health in Melbourne, Australia and one of the largest cardiac care services in Australia. He was also Professor of Medicine and Cardiology at Monash University in Melbourne and Executive Director of the Monash Cardiovascular Research Centre at Monash University.
With more than 25 years of experience as a clinical and interventional cardiologist, Professor Meredith has performed more than 12,000 cardiac and coronary procedures, published more than 350 peer-reviewed manuscripts and book chapters and championed many new treatment paradigms into daily clinical practice. He has been the chief or principal investigator on more than 50 major international multi-center trials and was the global principal investigator for the Boston Scientific Lotus™ Valve REPRISE research program.
Professor Meredith has served on numerous national and international professional boards, government committees and advisory boards including the Australian Department of Health and Human Services, Cardiac Services Review and the Federal Government Department of Health & Aging Cardiac Prostheses Advisory Group. He received an Order of Australia (AM) for outstanding service to medicine in the field of Cardiology as a clinician and researcher and through advisory roles with a range of public health organizations.
Professor Meredith completed his undergraduate medical education in Melbourne and his PhD at the Baker Institute before embarking on post-graduate training at the Brigham and Women’s Hospital and Harvard Medical School in Boston.
Joe Fitzgerald is Executive Vice President and President, Rhythm Management for Boston Scientific and a member of its Executive Committee.
Prior to his current role, Fitzgerald was President of Boston Scientific's Endovascular Unit, which included the Company's Peripheral Interventions, Electrophysiology, Neurovascular and IVUS businesses. Previously, he held a number of senior leadership positions at Boston Scientific, including President of our Electrophysiology business and Vice President of Global Marketing and U.S. Sales for the Company's Neurovascular business.
Edward Mackey is Executive Vice President, Global Operations for Boston Scientific and a member of its Executive Committee. In this role, he is responsible for Global Manufacturing and Supply Chain, Quality and Regulatory Affairs, Information Technology, Global Business Services, Global Business Excellence, Corporate Research and Development and Corporate Marketing and Market Access. Mackey is the chair of the Boston Scientific Technical Executive Committee and is responsible for overseeing emerging areas such as digital health and the cancer solutions team.
Mackey is a seasoned executive with a track record of delivering strong results, leading large teams and developing innovative strategies. Prior to joining Boston Scientific in 2015, Mackey was Worldwide President of DePuy Synthes Power Tools, a division of Johnson & Johnson, after having served as Vice President of Integration for Johnson & Johnson’s acquisition of Synthes.
Earlier in his career, Mackey held management positions in Operations, Quality and Product Development at Raytheon’s Missile Systems division. In 1995, he moved to Johnson & Johnson Orthopaedics as a plant manager and progressed through a series of manufacturing and supply chain leadership roles, becoming Worldwide Vice President of Supply Chain and Manufacturing for DePuy in 2007.
Mackey holds a B.S. in Mechanical Engineering from Worcester Polytechnic Institute and an M.B.A. from the University of Massachusetts.
Jeff Mirviss is Senior Vice President and President, Peripheral Interventions for Boston Scientific and a member of its Executive Committee. In that capacity he is responsible for developing and bringing to market innovative solutions for treating patients with high blood pressure, vascular system blockages and cancer.
Mirviss has more than 23 years of experience in medical device and pharmaceutical general management, marketing and sales. He has held positions of increasing responsibility since 1997 at Boston Scientific.
In addition to his roles at Boston Scientific, Mirviss has worked for companies ranging in size from a pre-revenue venture-backed medical device startup to Dow 30 companies.
A resident of Plymouth, Minnesota, Mirviss holds a Bachelor’s degree from the University of Minnesota and an MBA from the University of St. Thomas.
Maulik Nanavaty is Senior Vice President and President, Neuromodulation Division for Boston Scientific and a member of its Executive Committee. In this role, he is responsible for the innovation leader in less-invasive microelectronic implantable technologies used to treat chronic neuropathic pain.
Prior to his current role, Nanavaty was President, Representative Director of Boston Scientific Japan. Previously, he was Vice President and General Manager of the Company's Interventional Cardiology business in Japan. During his tenure, Nanavaty managed the successful expansion of Cardiology business in that country. He joined Boston Scientific in 2005 as Vice President for Corporate Strategy for Japan, where he led business transformation and increased operational efficiency.
Prior to joining Boston Scientific, Nanavaty spent 16 years working in various executive positions at Baxter International, Inc., and Baxter Japan.
Nanavaty earned a Ph.D. in Pharmaceutical Sciences from the University of Illinois and a M.B.A. from the University of Chicago.
Nanavaty is a member of the Board of Directors for the California Health Institute (CHI). CHI is an independent 501(c)(6) organization devoted to researching and advocating policy to forward the interests of California's biomedical community.
David A. Pierce is our executive vice president and president of MedSurg, a position he has held since April 2018. In this role, he will have direct responsibility for Urology and Pelvic Health, Endoscopy business, Canada and the Latin America region, and Corporate Marketing and Market Access. Prior to his current role, Mr. Pierce served as senior vice president and president, Urology and Pelvic Health, since July 2016; senior vice president and president, Endoscopy since 2011, and vice president, Marketing for Endoscopy as well as group marketing director in the Endoscopy business. He joined Boston Scientific in 1991 as a territory manager before assuming management-level positions of increasing responsibility. Prior to joining Boston Scientific, Mr. Pierce also served as senior sales representative for Airborne Express and as a Captain in the United States Army. He earned a B.S. in Business Administration from Norwich University and an M.B.A. from Boston University.
Brad Sorenson is our senior vice president, Manufacturing and Supply Chain, a position he has held since November 2014. In this role, he is responsible for the global manufacturing and distribution of our products. Prior to his current role, he served as multi-site vice president, operations from 2008 to 2014. Mr. Sorenson held a variety of operations positions at Boston Scientific, supporting the Cardiac Rhythm Management, Neuromodulation, Interventional Cardiology, Peripheral Interventions and Structural Heart businesses and has more than 20 years of medical device manufacturing experience. Before joining Boston Scientific, he was president and chief operating officer of QRS Diagnostic and held manufacturing management positions at Federal Cartridge. Mr. Sorenson earned a B.A. in Economics from Gustavus Adolphus College and an M.B.A. from the University of Minnesota.
Eric Thépaut is our senior vice president and president, Europe, Middle East and Africa, a position he has held since January 2018. Prior to his current role, he was senior vice president and president, Europe from January 2015 to December 2017 and served as vice president Interventional Cardiology & Structural Heart, Europe, from December 2012 to December 2015. He joined Boston Scientific Europe, in 1996, as a business finance manager and earned roles of increasing responsibility in marketing and finance including; vice president, Finance, Europe, general manager and vice president, France, and general manager and vice president of the France Group, comprised of France, Benelux and Middle East North Africa. Before joining Boston Scientific, Mr. Thépaut held management positions in treasury operations and auditing at Nestlé and financial planning and analysis at Apple Computer. Mr. Thépaut earned his M.B.A. at Paris Dauphine University.
Warren Wang is our senior vice president and president, Asia Pacific, a position he has held since January 2018. In this role, he is responsible for the overseeing the continued growth of our company in Asia Pacific and the ongoing development of our leadership teams. Prior to his current role, he was president and managing director, North Asia from January 2016 to December 2017. Mr. Wang joined Boston Scientific in 2012 as vice president and managing director for China. Mr. Wang is known for successfully championing strategic collaborations with local organizations to increase our presence and local innovation development in China, such as our work with Frankenman Medical Equipment, PINS Medical Equipment Company, Tsinghua University and the International Health Industry Innovation Fund. Mr. Wang earned his Bachelor in Economics from the University of International Business and Economics, Beijing and a M.B.A. in Marketing and Finance from the University of Chicago, Booth School of Business.
Nelda J. Connors has been a director of Boston Scientific since December 2009. Ms. Connors is the founder, Chairwoman and Chief Executive Officer of Pine Grove Holdings, LLC, which invests in companies that offer original equipment, manufactured and remanufactured products, and aftermarket services. She served as President and Chief Executive Officer of Atkore International Inc. from December 2010 until June 2011. Atkore, formerly the Electrical and Metal Products division of Tyco International, became a privately-held company in December 2010. Ms. Connors served as President of this Tyco division from 2008 through 2010. Prior to joining Tyco, she served as Vice President at Eaton Corporation from 2002 to 2008 where she held several positions in operations, continuous improvement, and general management. Prior to joining Eaton, Ms. Connors was employed in a number of executive and management capacities in the automotive industry. Her work over twenty-five years has involved responsibilities in the U.S., Europe, and Asia. Ms. Connors is a Class B director of the Federal Reserve Bank of Chicago, a director of Claror, Inc., Vesuvius plc and EchoGlobal Logistics, Inc., and an appointed member for the Takata Independent Quality Assurance Panel. She previously served on the board of directors of Atkore and Blount International. Ms. Connors holds B.S. and M.S. degrees in mechanical engineering from the University of Dayton.
Charles J. Dockendorff has been a director of Boston Scientific since April 2015. He was Executive Vice President and Chief Financial Officer of Covidien plc, a publicly traded medical device and supplies company, a position he held at Covidien and its predecessor, Tyco Healthcare, from 1995 to 2015. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as Controller and was named Vice President and Controller in 1994. He was appointed CFO of Tyco Healthcare in 1995. Prior to joining Kendall/Tyco Healthcare, Mr. Dockendorff was the Chief Financial Officer, Vice President of Finance and Treasurer of Epsco Inc. and Infrared Industries, Inc. In addition, Mr. Dockendorff worked as an accountant for Arthur Young & Company (now Ernst & Young) and the General Motors Corporation. Mr. Dockendorff is a director of Haemonetics Corporation and Keysight Technologies, Inc. Mr. Dockendorff holds a bachelor’s degree in accounting from the University of Massachusetts at Amherst and a M.S. in finance from Bentley College.
Yoshiaki Fujimori has been a director of Boston Scientific since July 2016. He is currently an adviser to the LIXIL Group Corporation, a position he has held since June 2016, and was the President and CEO of the LIXIL Group Corporation from August 2011 to June 2016. Prior to joining LIXIL, he was Chairman, President and CEO of GE Japan from January 2008 to June 2011. In his 25 years at GE, beginning in October 1986, he held a variety of positions including Senior Vice President and CEO of a number of Asian and global business divisions including Medical Systems, Plastics, and Capital. During his time at GE, Mr. Fujimori also served as a member of the Corporate Executive Council from 2001 to 2010. Mr. Fujimori started his career at Japanese trading company, Nissho Iwai Corporation (now Sojitz), where he worked from April 1975 to September 1986. Mr. Fujimori currently serves as an External Director of Tokyo Electric Power Company, a role he has held since June 2012 and External Director for Takeda Pharmaceutical Company Limited, a role he has held since June 2016. Also, from June 2014 to June 2016, Mr. Fujimori served as Chairman of the Japan Construction Material & Housing Equipment Industries Federation. Mr. Fujimori received a bachelor’s degree in petroleum engineering from the University of Tokyo and his master’s degree from Carnegie Mellon Graduate School of Business, where he serves as a lifetime member of the Board of Trustees.
Donna A. James has been a director of Boston Scientific since July 2015. She is the founder of Lardon & Associates LLC, a business development and executive advisory services firm, where she has served as president and managing director since April 2006. Ms. James has more than 30 years of diverse management and leadership experience, including her experience at Nationwide Insurance and Financial Services, where she served in a variety of roles beginning in 1981. In her time at Nationwide, she served in several leadership roles, including serving as president of Nationwide Strategic Investments, a division of Nationwide Insurance Company, from 2003 to 2006 at which time she had direct responsibility for developing and executing strategies for U.S. and global financial services subsidiaries and affiliates. Ms. James also is the founder and chair of The Center for Healthy Families, a non-profit in Columbus, Ohio, and the former president and appointed chair of the National Women’s Business Council. Ms. James currently serves as a director of Time Warner Cable Inc., L Brands, Inc., and Marathon Petroleum Inc., as well as FIS Group, a privately-held asset management and investment advisory firm. She received her B.S. in Accounting from North Carolina A&T State University.
John E. Sununu has been a director since April 2009. From 2003 to 2009, Senator Sununu served as a U.S. Senator from New Hampshire. He was a member of the Committees on Banking, Commerce, Finance and Foreign Relations, and he was appointed the Congressional Representative to the United Nations General Assembly. Before his election to the Senate, Senator Sununu served three terms as a Member of the U.S. House of Representatives from New Hampshire’s 1st District from 1996 to 2002. He was Vice Chairman of the Budget Committee and a member of the Appropriations Committee. During his twelve years in Congress, he drafted and helped pass several important pieces of legislation, including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act. Prior to serving in Congress, Senator Sununu served as Chief Financial Officer for Teletrol Systems, a manufacturer of building control systems. Mr. Sununu formerly served as a director of Time Warner Cable Inc. until May 2016. He holds B.S. and M.S. degrees in Mechanical Engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
Edward J. Ludwig has been a director of Boston Scientific since March 2014. Mr. Ludwig is the former Chairman of the Board of Becton, Dickinson and Company (“BDX”), a global medical technology company, having served in that position from February 2002 through June 2012. He also served as BDX’s Chief Executive Officer from January 2000 to September 2011 and as its President from May 1999 to December 2008. Mr. Ludwig joined BDX as a Senior Financial Analyst in 1979. Prior to joining BDX, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now PricewaterhouseCoopers) where he earned his CPA and as a financial and strategic analyst at Kidde, Inc. Mr. Ludwig serves as Lead Director on Aetna Inc.’s Board of Directors and chairs its Finance Committee and is a member of the Board of Directors of Xylem, Inc. Additionally, Mr. Ludwig served as Vice Chair of the Board of Trustees of the Hackensack University Medical Center Network from 2012 to 2015. Mr. Ludwig received a B.A. degree in economics and accounting from The College of the Holy Cross and a M.B.A. degree from Columbia University.
Stephen P. MacMillan has been a director of Boston Scientific since April 2015. He is currently the Chairman, President and CEO of Hologic, Inc., a position he has held since June 2015, and he served as President and CEO of Hologic, Inc., since December 2013. Prior to assuming his role with Hologic, Mr. MacMillan was the Chief Executive Officer of sBioMed, LLC, a medical research company, from October 2012 to December 2013. From 2003 to 2012, Mr. MacMillan served in various roles at Stryker Corporation, including Chief Operating Officer from June 2003 to January 2005, President from June 2003 to February 2012, Chief Executive Officer from January 2005 to February 2012 and Chairman from January 2010 to February 2012. Prior to 2003, Mr. MacMillan was a senior executive with Pharmacia Corporation where he oversaw five global businesses. Prior to joining Pharmacia, Mr. MacMillan spent 11 years with Johnson & Johnson in a variety of senior roles both in the U.S. and Europe, including President of the joint venture between Johnson & Johnson and Merck. Mr. MacMillan began his career with Procter and Gamble in 1985. Additionally, Mr. MacMillan served on the board of directors of Texas Instruments Inc. from 2008 to 2012 and Alere, Inc. from 2013 to 2015. Mr. MacMillan received a Bachelor of Arts degree in Economics from Davidson College and is a graduate of Harvard Business School’s Advanced Management Program.
Michael F. Mahoney became our Chairman of the Board, President, Chief Executive Officer and director in May 2016. He served as President, Chief Executive Officer and director from November 2012 to April 2016. He served as President of the Company from October 2011 to October 2012. As President of the Company, he was specifically responsible for our Cardiac Rhythm Management and Endoscopy businesses, as well as certain corporate functions. Prior to joining the Company, he was Worldwide Chairman of the Medical Devices and Diagnostics division of Johnson & Johnson from January 2011 to September 2011 overseeing 50,000 employees and seven franchises. Prior to assuming this position, Mr. Mahoney served as Worldwide Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, Mr. Mahoney served as President and Chief Executive Officer of Global Healthcare Exchange (GHX), a provider of supply chain solutions and services that brings together hospitals, manufacturers, distributors and group purchasing organizations. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. He currently serves on the board of directors of Baxter International, Inc. Mr. Mahoney earned a B.B.A. in Finance from the University of Iowa and a M.B.A. from Wake Forest University.
David J. Roux has been a director of Boston Scientific since January 2014. Mr. Roux is a co-founder and Senior Director of Silver Lake, a private equity firm focused on technology investing. He was formerly Chairman and Chief Executive Officer of Liberate Technologies, Executive Vice President at Oracle Corporation and Senior Vice President at Lotus Development. Mr. Roux served as a member of the boards of directors of Avaya Inc. from December 2008 until December 2012, Avaya Holdings Corp. from January 2007 until December 2012, Serena Software, Inc. from March 2006 until March 2011 and Intelsat S.A. from May 2010 until January 2012. Mr. Roux holds an M.B.A. from Harvard Business School and an M. Phil. from King’s College, Cambridge University. He is a graduate of Harvard College.
Ellen M. Zane
Ellen M. Zane, has been a director of Boston Scientific since April 2016. Ms. Zane is CEO Emeritus and Vice Chair of the board of trustees at Tufts Medical Center & Floating Hospital for Children, and from 2004 to 2011, she served as its President and Chief Executive Officer. From May 1994 to January 2004, Ms. Zane served as Network President for Partners Healthcare System, a physician/hospital network sponsored by the Harvard affiliated Massachusetts General Hospital and Brigham and Women’s Hospital. Prior to 2004, Ms. Zane served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane is also currently a member of the board of directors at Brooks Automation, a publicly traded global provider of automation, vacuum and instrumentation solutions, Parexel International Corporation, a publicly traded global bio-pharmaceutical services company and Press Ganey, a publicly traded preeminent provider of patient experience measurement and data in acute hospital settings and ambulatory settings, Century Capital Management, LLC, a private mutual fund company, Fiduciary Trust Company, a privately owned wealth management company and AgNovos Healthcare, LLC a privately held medical device company, focused on bone health. Ms. Zane previously served as a director of Lincare Holdings Inc. until it was acquired in August 2012. Ms. Zane holds a Professional Director Certification from the American College of Corporate Directors. Ms. Zane earned her B.A. from George Washington University and her M.A. from Catholic University of America, both in Audiology and Speech-Language Pathology.